Entera Bio Ltd. business relationships
Companies named in Entera Bio Ltd.’s 10-K filed 2026-03-27, and public companies whose annual reports name Entera Bio Ltd.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 22 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Layers: PeptidesGLP-1 & obesity
Named in Entera Bio Ltd.’s annual report 4
“Amended and Restated Collaboration and License Agreement, dated February 3, 2026, by and among Entera Bio Ltd., OPKO Health, Inc. and OPKO Biologics Ltd. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on February 4, 2026)” SEC filing
“...we announced new in vivo PK/PD data supporting the development of a proprietary long-acting PTH (LA-PTH) analog, which is being developed as part of a material transfer and collaboration agreement with OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. ("OPKO"), utilizing our N-Tab ® platform.” SEC filing
“Amended and Restated Collaboration and License Agreement, dated February 3, 2026, by and among Entera Bio Ltd., OPKO Health, Inc. and OPKO Biologics Ltd. (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on February 4, 2026)” SEC filing
“...we announced new in vivo PK/PD data supporting the development of a proprietary long-acting PTH (LA-PTH) analog, which is being developed as part of a material transfer and collaboration agreement with OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. ("OPKO"), utilizing our N-Tab ® platform.” SEC filing
Companies whose annual reports name Entera Bio Ltd. 1
“OPK-88006 (Oral): In collaboration with Entera Bio Ltd. ("Entera"), we are advancing a once-daily tablet formulation of OPK-88006.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.